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Most recent report of results to date:
To pursue the development of radiolabeled immunotoxins (RIT) for colon cancer, it was
first necessary to identify an immunotoxin (IT) that could selectively kill colon cancer cell
lines.   Recently, our  collaborators in the  Vallera laboratory have observed that  potent
recombinant IT can be synthesized using recombinant single chain antibodies (sFv) spliced
to truncated diphtheria toxin (DT) consisting of the first 390 amino acids of native DT. DT
was chosen as a toxin because it is a catalytic bacterial toxin that is easily manipulated in
genetic  engineering studies.  Also,  the  Vallera  lab has  developed new procedures  for
preparing the sFv fusion toxins from bacterial inclusion bodies such as DT and another
good genetic engineering toxin pseudomonas exotoxin (PE) based on detergent refolding.
This allows for enhanced yields and higher purity that is essential for generating the protein
that will be needed for preparation of larger amounts of RIT for therapy.  Many potential
sFvs were considered for targeting colon cancer. The best results have been obtained with
an sFv recognizing EpCam. EpCam, also known as ESA or EGP40, is a 40 kDa epithelial
transmembrane glycoprotein found on the basolateral surface of simple, pseudostratified,
and transitional epithelia.  It has been found overexpressed on 81% of adenocarcinomas of
the colon (Went et al. Human pathology 35:122, 2004).  EpCam sliced to DT (DTEpCam)
was highly potent in studies in which we measured its ability to inhibit the proliferation of
the HT-29 and COLO 205 colon cancer cell lines since we measured its IC50 at 1-2 x 10-2
nM. Potency is important, but is also critical that DTEpCam is selective in its cytotoxicity
against EpCam-expressing target colon cancer cells.  The activity of DTEpCam was highly
selective since irrelevant control IT that did not recognize any markers on cancer cells, did
not show any activity against the same colon cancer cell lines.  Also, blocking studies were
performed in  which DTEpCam was  mixed with the  EpCam sFv that was  synthesized
without any toxin attached.  The proliferation studies showed that EpCam sFv was able to
block the  killing of  the  EpCam expressing cells  by DTEpCam.  An irrelevant control
protein, 1D10Fc was unable to block. Together, these studies indicated that EpCam was
exquisitely selective.  In order to produce an IT of even greater potency, we used a toxin
containing the Golgi retention sequence KDEL.  The same EpCam sFv was spliced to
truncated PE containing the terminal KDEL sequence. The addition of KDEL enhanced the
potency of the EpCam sFv IT at least 6 logs or 1000-fold with an IC50 of 2 to 7 x 10-8 nM.
This conjugate was also shown to be highly selective.  Taken together, all of these studies
indicate  that  in  vitro  experiments  have  shown that  we  have  a  highly  potent  IT  that
selectively kills colon cancer cells.
The next step was to show that the EpCam IT had the ability to inhibit the growth of flank
tumors in vivo in nude mice. The same human colon tumor cells, HT29 used in the in vitro
studies were injected into the flank of nude mice. Tumor cells were injected into groups of
mice  and when tumors  reached the  size of 0.5  cm3,  we injected  our  best-performing
EpCam IT called EpCamKDEL intratumorally. There was a significant drop in tumor size
indicating  that  this  agent  was  very  effective  against  human  colon  cancer.  Since  the
EpCamKDEL was injected intratumorally, it did not have to travel through the systemic
circulation to find its target. Our next step will be to inject EpCamKDEL intravenously into
mice with flank tumors to determine if EpCamKDEL has the ability to migrate to the tumor
systemically.
The next step was to radiolabel EpCamKDEL to see whether it could serve as an RIT. We
radiolabeled EpCam with 111In as a surrogate for 90Y and then incubated it with HT29.
The labeling efficiency was over 90% indicating that a high percentage  of the protein
molecules could be readily radiolabeled. However, the immunoreactivity was only 20%
indicating that only 20% of those molecules were able to specifically bind antigen once
they were radiolabeled. We are currently determining whether this labeling procedure is too
harsh on the recombinant protein or whether some other labeling procedure might result in
a higher level of immunoreactivity.
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